Plain language summary of a Phase II study design to test different doses of BI 1819479 in people with idiopathic pulmonary fibrosis

Future Rare Diseases · Available online 5 Jun 2026 · In press · Journal article · DOI 10.1080/23995270.2026.2665393

Authors being retrieved — see the publisher record. https://doi.org/10.1080/23995270.2026.2665393

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

How I treat Rett syndrome: impact of trofinetide on symptoms and comorbidities of the disease · Future Rare Diseases · 2026 · Same journal
Physician perspectives on practical implementation of identification & diagnosis of ATTRv-PN Amyloidosis: A case vignette series · Future Rare Diseases · 2025 · Same journal
Plain language summary: Patient journey and treatment patterns in progressive pulmonary fibrosis · Future Rare Diseases · 2025 · Same journal
AIRLEAF ® –a study of verducatib as a new kind of treatment for bronchiectasis: a plain language summary · Future Rare Diseases · 2025 · Same journal
Gastrointestinal symptoms and healthcare utilization among individuals with Rett syndrome at a center of excellence · Future Rare Diseases · 2025 · Same journal
A plain language summary of the phase 3 explorer7 study of concizumab prophylaxis for people with hemophilia with inhibitors · Future Rare Diseases · 2025 · Same journal
How I treat Rett syndrome with trofinetide: changes in dosing frequency and administration with rice cereal · Future Rare Diseases · 2025 · Same journal
rIX-FP prophylaxis in patients with hemophilia B · Future Rare Diseases · 2025 · Same journal
Pegcetacoplan for C3G and other complement-mediated glomerular diseases: plain language summary of the DISCOVERY study · Future Rare Diseases · 2025 · Same journal
A plain language summary of a study of long-term outcomes in patients with IgA nephropathy from the UK National Registry of Rare Kidney Diseases (RaDaR) · Future Rare Diseases · 2025 · Same journal